IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Berzofsky et al.

Application No. 10/532.374

Filed: April 21, 2005

FILED VIA EFS

Confirmation No. 4276

For: METHODS TO PREVENT TUMOR RECURRENCE BY BLOCKADE OF TGF-

BETA

Examiner: Sheela I Huff

Art Unit: 1643

Attorney Reference No. 4239-67016-02

FILED VIA THE ELECTRONIC FILING SYSTEM UNITED STATES PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and submitted herewith are four English-language document. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Supplemental Information Disclosure Statement (IDS) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the Supplemental IDS filed herewith was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this Supplemental IDS. Please charge any additional fees which may be required in connection with filing this Supplemental IDS, or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this Supplemental IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted.

KLAROUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

By /Anne Carlson/ Anne Carlson, Ph.D.

Registration No. 47,472